The U.S. Food and Drug Administration (FDA) already declared that shortages of popular GLP-1 medications have ended, CNN ...

VinFuture Prize holds the distinction of being the first major international science and technology award to recognize and ...

GLP-1 weight-loss drugs are reshaping dairy demand by curbing cravings for processed, fatty, and sugary products, fueling a ...

In patients with T2D, GLP-1s don’t increase the risk for acute pancreatitis, mitigate the risk for complications in those who ...

Adults with obesity using a GLP-1 have a similar risk for obesity-related cancers as those who undergo bariatric surgery, ...

Unless you are from another planet, you’ve heard all about the new weight loss medications taking the world by storm. These ...

Novo Nordisk's limited-time coupon on Wegovy was simultaneously promoted by telehealth companies Ro and Wegovy ...

A growing number of South Dakotans are shedding pounds thanks to GLP-1 medications, but now they’re hitting a roadblock.

Glucagon-like peptide 1 receptor agonist treatment is not associated with an increased risk for psychiatric adverse events or worsening depressive symptoms.

The health services arm of The Cigna Group CI, Evernorth, recently introduced a pharmacy benefit offering designed to enhance ...

Glucagon-like peptide-1 receptor agonists may cut the risk of obesity-related cancer in patients being treated for diabetes and obesity.

There is growing evidence that Ozempic and other GLP-1 receptor agonist drugs might help people drink less alcohol, but more ...